Allergan Plc announced that struck a global development and commercialisation agreement with AstraZeneca Plc regarding investigational antibiotic combination ATM-AVI. The fixed-dose combination of aztreonam and avibactam will be studied as treatment for serious infections triggered by metallo βlactamase MBL-producing Gram-negative pathogens. The terms of the deal give Allergan commercialisation rights in the US and Canada, with AstraZeneca holding them in all other countries.